Open Access. Powered by Scholars. Published by Universities.®
- Discipline
-
- Neoplasms (3)
- Public Health (3)
- Anatomy (2)
- Health Services Research (2)
- Medical Sciences (2)
-
- Allergy and Immunology (1)
- Analytical, Diagnostic and Therapeutic Techniques and Equipment (1)
- Bioethics and Medical Ethics (1)
- Body Regions (1)
- Cardiology (1)
- Clinical Epidemiology (1)
- Community Health and Preventive Medicine (1)
- Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1)
- Endocrine System Diseases (1)
- Endocrinology, Diabetes, and Metabolism (1)
- Health Services Administration (1)
- Health and Medical Administration (1)
- Hemic and Immune Systems (1)
- Hemic and Lymphatic Diseases (1)
- Hepatology (1)
- Infectious Disease (1)
- Medical Genetics (1)
- Medical Immunology (1)
- Other Analytical, Diagnostic and Therapeutic Techniques and Equipment (1)
- Patient Safety (1)
- Preventive Medicine (1)
- Keyword
-
- Antibody (1)
- Bioethics (1)
- Blood cancer (1)
- Breast cancer (1)
- COVID-19 (1)
-
- Cardiac metastases (1)
- Dyspnea (1)
- Electronic health records (1)
- Family communication (1)
- Health care resource utilization (1)
- Health-related outcomes (1)
- Hematology (1)
- Hepatitis (1)
- Hepatocellular carcinoma (1)
- Lynch syndrome (1)
- MRNA vaccine (1)
- Malignancy (1)
- Medical genetics (1)
- Multimodality imaging (1)
- Postmortem disclosure (1)
- Preventive care (1)
- Recurrence (1)
- SARS-CoV-2 (1)
- Seroconversion (1)
- Survivorship (1)
- Type 2 diabetes (1)
Articles 1 - 4 of 4
Full-Text Articles in Oncology
Should Health Systems Share Genetic Findings With At-Risk Relatives When The Proband Is Deceased? Interviews With Individuals Diagnosed With Lynch Syndrome, Jessica Ezzell Hunter, Jennifer L. Schneider, Alison J. Firemark, James V. Davis, Sara Gille, Pamala A. Pawloski, Su-Ying Liang, Victoria Schlieder, Alanna Kulchak Rahm
Should Health Systems Share Genetic Findings With At-Risk Relatives When The Proband Is Deceased? Interviews With Individuals Diagnosed With Lynch Syndrome, Jessica Ezzell Hunter, Jennifer L. Schneider, Alison J. Firemark, James V. Davis, Sara Gille, Pamala A. Pawloski, Su-Ying Liang, Victoria Schlieder, Alanna Kulchak Rahm
Journal of Patient-Centered Research and Reviews
Purpose: Genetic information has health implications for patients and their biological relatives. Death of a patient before sharing a genetic diagnosis with at-risk relatives is a missed opportunity to provide important information that could guide interventions to minimize cancer-related morbidity and mortality in relatives.
Methods: We performed semi-structured interviews with individuals diagnosed with Lynch syndrome at 1 of 4 health systems to explore their perspectives on whether health systems should share genetic risk information with relatives following a patient’s death. An inductive, open-coding approach was used to analyze audio-recorded content, with software-generated code reports undergoing iterative comparative analysis by a …
Cardiac Metastasis After Curative Treatment Of Hepatocellular Carcinoma: Risk Factors, Treatment Options, And Prognosis, Gaurav Jain, Mathew Otto, Mubeen Khan Mohammed Abdul, Manpreet Chadha, Ajay Sahajpal
Cardiac Metastasis After Curative Treatment Of Hepatocellular Carcinoma: Risk Factors, Treatment Options, And Prognosis, Gaurav Jain, Mathew Otto, Mubeen Khan Mohammed Abdul, Manpreet Chadha, Ajay Sahajpal
Journal of Patient-Centered Research and Reviews
Hepatocellular carcinoma (HCC) is primary hepatic malignancy with a high incidence of recurrence. The risk of recurrence directly correlates to patient’s overall prognosis. Management of advanced HCC involves a combination of surgical resection, locoregional therapy, and systemic treatment. Distant metastases are rare, and intraventricular cardiac metastases are even more infrequent. This brief review details an illustrative case of cardiac metastasis after curative treatment of primary HCC and then summarizes the literature on risk factors, treatment options, and patient prognosis in the setting of distant metastases from HCC. Prognosis of metastasis to the heart is generally poor, and available evidence emphasizes …
Real-World Third Covid-19 Vaccine Dosing And Antibody Response In Patients With Hematologic Malignancies, Michael A. Thompson, Sigrun Hallmeyer, Veronica E. Fitzpatrick, Yunqi Liao, Michael P. Mullane, Stephen C. Medlin, Kenneth Copeland, James L. Weese
Real-World Third Covid-19 Vaccine Dosing And Antibody Response In Patients With Hematologic Malignancies, Michael A. Thompson, Sigrun Hallmeyer, Veronica E. Fitzpatrick, Yunqi Liao, Michael P. Mullane, Stephen C. Medlin, Kenneth Copeland, James L. Weese
Journal of Patient-Centered Research and Reviews
Purpose: This study sought to describe the changes in immune response to a third dose of either Pfizer’s or Moderna’s COVID-19 mRNA vaccine (3V) among patients with hematologic malignancies, as well as associated characteristics
Methods: This retrospective cohort study analyzed pre-3V and post-3V data on 493 patients diagnosed with hematologic malignancies across a large Midwestern health system between August 28, 2021, and November 1, 2021. For antibody testing, S1 spike antigen of the SARS-CoV-2 virus titer was used to determine serostatus.
Results: Among 493 participants, 274 (55.6%) were seropositive both pre- and post-3V (+/+) while 115 (23.3%) seroconverted to positive …
Differences In Health-Related Outcomes And Health Care Resource Utilization In Breast Cancer Survivors With And Without Type 2 Diabetes, Susan Storey, Zuoyi Zhang, Xiao Luo, Megan Metzger, Amrutha Ravali Jakka, Kun Huang, Diane Von Ah
Differences In Health-Related Outcomes And Health Care Resource Utilization In Breast Cancer Survivors With And Without Type 2 Diabetes, Susan Storey, Zuoyi Zhang, Xiao Luo, Megan Metzger, Amrutha Ravali Jakka, Kun Huang, Diane Von Ah
Journal of Patient-Centered Research and Reviews
Purpose: Up to 74% of breast cancer survivors (BCS) have at least one preexisting comorbid condition, with diabetes (type 2) common. The purpose of this study was to examine differences in health-related outcomes (anemia, neutropenia, and infection) and utilization of health care resources (inpatient, outpatient, and emergency visits) in BCS with and without diabetes.
Methods: In this retrospective cohort study, data were leveraged from the electronic health records of a large health network linked to the Indiana State Cancer Registry. BCS diagnosed between January 2007 and December 2017 and who had received chemotherapy were included. Multivariable logistic regression and generalized …